CD30 is a member of the tumor necrosis factor ... 75 The development of a novel antibody-drug conjugate (ADC), BV (also referred to as SGN-35 or cAC10-vcMMAE), seemed to overcome some of the ...

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response ...

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

All these issues had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently received ... and the merits of targeting the CD30 antigen became apparent.

Anti-CD30 therapies Emerging Drugs Brentuximab vedotin – Seagen/Takeda Brentuximab Vedotin (ADCETRIS) is an antibody-drug conjugate (ADC) therapy developed by Seagen and its Takeda Oncology.

ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma, and has been previously approved as a therapy for adult patients in Europe in six distinct ...

First-line for CD30-negative PTCL. ~30-40% CR rate Brentuximab Vedotin + CHP Anti-CD30 ADC with chemotherapy (CHP). First-line for CD30-positive PTCL. ~54-86% ORR; ~33-57% CR rate Histone ...

data will be presented from a new CD30-directed ADC that employs our novel camptothecin ADC technology and is being investigated as a potential future treatment option in CD30-expressing lymphomas.” ...

reflected by the fact that it wasn’t until 2011 that the second ADC product was approved by the FDA – Seattle Genetics’ Adcetris (brentuximab vedotin), an anti-CD30 ADC for the treatment of ...

The CD30-directed antibody-drug conjugate has been ... a blockbuster by way of the company’s $43 billion acquisition of ADC specialist Seagen in 2023. Takeda holds rights to commercialize ...

Researchers from Tubulis GmbH presented preclinical data for a CD30-targeting antibody-drug conjugate (ADC), TUB-010, being developed as a potential anticancer immunotherapy candidate. TUB-010, a ...